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Abstract
Background: Eosinophilic airway inflammation has successfully been used to tailor anti-inflammatory therapy in
chronic obstructive pulmonary disease (COPD). Airway hyperresponsiveness (AHR) by indirect challenges is
associated with airway inflammation. We hypothesized that AHR to inhaled mannitol captures eosinophilia in
induced sputum in COPD.
Methods: Twenty-eight patients (age 58 ± 7.8 yr, packyears 40 ± 15.5, post-bronchodilator FEV1 77 ± 14.0%
predicted, no inhaled steroids ≥4 wks) with mild-moderate COPD (GOLD I-II) completed two randomized visits with
hypertonic saline-induced sputum and mannitol challenge (including sputum collection). AHR to mannitol was
expressed as response-dose-ratio (RDR) and related to cell counts, ECP, MPO and IL-8 levels in sputum.
Results: There was a positive correlation between RDR to mannitol and eosinophil numbers (r = 0.47, p = 0.03)
and level of IL-8 (r = 0.46, p = 0.04) in hypertonic saline-induced sputum. Furthermore, significant correlations were
found between RDR and eosinophil numbers (r = 0.71, p = 0.001), level of ECP (r = 0.72, p = 0.001), IL-8 (r = 0.57,
p = 0.015) and MPO (r = 0.64, p = 0.007) in sputum collected after mannitol challenge. ROC-curves showed 60%
sensitivity and 100% specificity of RDR for >2.5% eosinophils in mannitol-induced sputum.
Conclusions: In mild-moderate COPD mannitol hyperresponsiveness is associated with biomarkers of airway
inflammation. The high specificity of mannitol challenge suggests that the test is particularly suitable to exclude
eosinophilic airways inflammation, which may facilitate individualized treatment in COPD.
Trial registration: Netherlands Trial Register (NTR): NTR1283
Introduction
Chronic obstructive pulmonary disease (COPD) is
an inflammatory airway disease characterized by non-
reversible airflow limitation [1]. Airflow limitation is
usually progressive and associated with an abnormal
inflammatory response of the lungs to noxious particles
or gasses. The treatment options in COPD are still lim-
ited and current efforts focus on therapy targeted to
particular phenotypes of the disease [1]. A non-invasive,
standardised way to measure and monitor airway
inflammation in COPD is hypertonic saline-induced
sputum [2]. Analysis of induced sputum provides infor-
mation about cell counts (eosinophils, neutrophils,
lymphocytes, macrophages) and cell activity by mediator
concentrations (e.g. ECP, MPO and IL-8).
In COPD patients the identification of sputum eosino-
philia has shown to be of clinical value as it predicts a
response to corticosteroids [3-5]. Furthermore, guiding
inhaled steroid therapy by sputum eosinophil counts
leads to a reduction in exacerbations in COPD, without
an increase in steroid dose [6]. These observations
demonstrate the value of identifying inflammatory sub-
phenotypes in the treatment of COPD. However, the
application of sputum analysis is somewhat limited by
the requirement of lab facilities and the not-directly
available results. Therefore, there is a need for adequate
surrogate markers of airway inflammation in COPD.
Airway hyperresponsiveness (AHR) may serve as a sur-
rogate measure of airway inflammation, since it is asso-
ciated with the presence of inflammatory cells and
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any medium, provided the original work is properly cited.release of mediators in the airways [7]. In particular, this
holds for indirect challenges, amongst which dry powder
mannitol challenge is relatively easy to apply [8,9]. Local
mannitol deposition results ina no s m o t i cc h a n g e ,l i k e l y
to induce the release of mediators from inflammatory
cells in the airways [10]. Studies in asthma showed that
AHR to mannitol is indeed related to the degree of eosi-
nophilic airway inflammation and is sensitive to treat-
ment with inhaled corticosteroids [11-13]. Interestingly, a
proof of concept study demonstrated that mannitol chal-
lenge might also be useful in identifying COPD patients
who will most likely benefit from inhaled corticosteroids
[14]. This may suggest that AHR to mannitol identifies
the degree of eosinophilic inflammation in COPD.
We postulated that AHR to mannitol captures eosino-
philic airway inflammation in adults with mild to moder-
ate COPD. Our aim was to test this hypothesis by
examining the relationship between AHR to mannitol and
markers of inflammation in hypertonic saline-induced
sputum, blood and exhaled air. As secondary aim, we
investigated whether similar relations can be observed
when using spontaneously produced sputum during or
directly after the mannitol challenge itself. Finally, we con-
structed receiver operating characteristic (ROC) curves
using AHR against sputum eosinophilia in COPD.
Methods
Patients
Thirty-two patients with mild to moderately severe COPD
were included from two respiratory clinics in Amsterdam,
The Netherlands. The definition of COPD was based on
GOLD [1]. Inclusion criteria were symptoms of dyspnea,
chronic cough or sputum production, current or ex-
smoker with at least 20 packyears of smoking history,
postbronchodilator FEV1 >1.5 liter and >50% of predicted
value, FEV1/FVC <0.70 and clinically stable for ≥ 4 weeks
prior to recruitment. Exclusion criteria were (inhaled) ster-
oid therapy or antibiotic treatment or exacerbation or
chest infection ≤ 4 weeks prior to recruitment, treatment
with b-blockers, respiratory disease other than COPD
including known asthma or allergic rhinitis and contra-
indications for challenge testing according to international
guidelines [15]. Patients were asked to withhold strenuous
exercise and smoking for 6 hrs and eating for 2 hrs;
caffeine and short-acting bronchodilators for 8 hrs; long-
acting bronchodilators for 48 hrs; short-acting anti-
cholinergics for 24 hrs; long-acting anti-cholinergics and
anti-histamines for 72 hrs; and leukotriene antagonists for
4 days prior to the mannitol challenge.
The study was approved by the Hospital Medical
Ethics Committee and all patients gave their written
informed consent. The study was registered in the Neth-
erlands trial register under NTR 1283, was designed,
performed and analysed by the authors, and was not
sponsored by others than the Academic Medical Centre,
Amsterdam, The Netherlands itself.
Study design
The study had a cross-sectional design with two studies
days comprising randomized challenges with hypertonic
saline and mannitol (figure 1). At a separate screening
visit, inclusion and exclusion criteria were examined,
postbronchodilator (400 μg salbutamol) spirometry was
performed and diffusion capacity was measured.
The sequence of the two study visits was randomized
[interval (median (range)):7(7-15) days]. On one day
sputum was induced by hypertonic saline and a venous
blood sample was obtained. On the other day exhaled
nitric oxide was measured first, followed by assessment
of atopy and mannitol challenge testing.
Measurements
Lung function
Spirometry (MasterscreenPneumo; Jaeger; Würzburg,
Germany) was performed by a trained respiratory tech-
nician according to the latest recommendations [16].
Diffusion capacity of the lung for carbon monoxide (DL,
CO) was measured according to the recommendations
using the single breath method and was corrected for
haemoglobin [17].
Mannitol challenge
Mannitol challenge was performed using a commercially
available kit (Pharmaxis Ltd; Sydney, Australia) as
described by Anderson et al [8]. Patients inhaled
sequential doses of 5, 10, 20, 40, 80, 160, 160 and 160
mg of mannitol via the inhaler. The test stopped when
15% fall in FEV1 was achieved or the cumulative dose of
635 mg had been administered. Response-dose-ratio
(RDR) was calculated as the%fall in FEV1 at the last
dose, divided by the total cumulative dose mannitol (%
fall.mg) in milligrams administered [18].
Figure 1 Study design.
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mannitol challenge, he or she was asked to expectorate.
This sputum was labeled as mannitol-induced sputum.
Sputum induction and processing
Prior to sputum induction, patients inhaled 200 μgs a l -
butamol. Sputum was induced by inhalation of NaCl
4.5% during 3 × 5 min intervals [19]. This sputum was
labeled as induced sputum.
Whole sputum samples were processed according to a
protocol that has been validated in our laboratory [20].
Differential cell counts were expressed as the percentage
of non-squamous cells. Absolute cell numbers were cal-
culated as (% cell × total cell count)/sputum weight.
Sputum samples containing >80% non-squamous cells
were excluded from analysis.
All sputum cell counts were performed by one experi-
enced and qualified technician blinded to the clinical
details. As an extra control 10% of the samples were
analyzed by a second technician.
Analysis of soluble markers in sputum supernatant
Levels of eosinophil cationic protein (ECP; detection
limit >60 pg/ml), myeloperoxidase (MPO; detection
limit >1.5 ng/ml), interleukin-8 (IL-8; detection limit
>19.1 pg/ml) and alpha-2-macroglobulin (a2M; detec-
tion limit >2.1 mg/ml) were measured by enzyme-linked
immunosorbent assays (ELISA) [21,22].
Exhaled Nitric Oxide (FeNO)
FeNO was measured with a portable rapid-response
chemoluminescent analyser (flow rate 50 mL/s; NIOX
System, Aerocrine, Sweden) according to recent guide-
lines [23].
Statistical analysis
The relationship between AHR to mannitol (RDR) and
the markers of airway inflammation were analyzed using
Pearson’s correlation coefficient (rp). Non-normally dis-
tributed data were log-transformed for further analysis.
If no cells were counted, a value of 0.1 was taken before
log-transformation. Receiver operating characteristic
(ROC) curves were constructed, using RDR against
eosinophilic vs non eosinophilic COPD (threshold 2.5%
sputum eosinophils). Wilcoxon signed rank test and
Bland-Altman analysis was used to compare cell counts
of the two sputum samples.
A sample size estimation showed that the detectable
value of the correlation (r) under the alternative hypoth-
esis with a sample of 23 patients (n) is between 1-0.55
(power = 0.808; alpha = 0.05). Therefore, thirty-two
patients were recruited taking into account an expected
10% drop-out rate and a 20% probability of missing or
non-valid data.
Results
Twenty-eight of the 32 patients completed the study
(table 1). Four patients dropped out for reasons of:
non-compliance with medication restrictions (n = 1), lost
to follow up (n = 1), FEV1 <1.2 litre prior to challenge (n
= 1) and inability to perform all techniques necessary to
measure lung function (n = 1). Two out of 28 mannitol
challenges were not completed for reasons of coughing
(n = 1) and tiredness (n = 1), but these patients were
included since this was not an exclusion criterion. Hyper-
tonic saline-induced sputum was collected in 28 patients
and mannitol-induced sputum in 21 patients.
Correlation of inflammatory markers in hypertonic saline-
induced sputum and blood with AHR to mannitol
The baseline values for airway hyperresponsiveness and
inflammatory markers are presented in table 2. Five
hypertonic saline-induced sputum samples were
excluded from analyses as a result of >80% non-squa-
mous cells on differential cell counts. There was a sig-
nificant positive correlation between the degree of AHR
to mannitol (RDR mannitol) and eosinophil counts (r =
0.47, p = 0.03, figure 2) per gram hypertonic saline-
induced sputum and with IL-8 levels (r = 0.46, p =
0.04). The correlation between RDR mannitol and blood
eosinophils was borderline significant (r = 0.38, p =
0.06, figure 2). No other correlations between RDR
mannitol and hypertonic saline-induced sputum para-
meters were found (Table 3). In addition, a significant,
positive association between RDR mannitol and the level
of FeNO (r = 0.67, p = 0.0002, figure 2) was observed.
When using PD15 to mannitol, the correlation coeffi-
cients with sputum and blood eosinophils counts were
-0.38 (p = 0.09) and -0.43 (p = 0.03), respectively.
Mannitol- induced sputum markers
Two out of 21 sputum samples were excluded from ana-
l y s e sa sar e s u l to f> 8 0 %n o n - squamous cells on differ-
ential cell counts. There were strongly significant
Table 1 Patient characteristics I
n =2 8
Male/Female (n) 23/5
Gold I/II (n) 12/16
Age (years) 58 ± 7.8
Current/ex-smoker (n) 12/16
Smoking history (pack years) 40 ± 15.5
Inhaled corticosteroids before study (n)1 4
Postbronchodilator FEV1 (L) 2.57 ± 0.6
Postbronchodilator FEV1 (%predicted) 77 ± 14.0
FEV1/FVC 0.55 ± 0.08
Atopy (n)3
DL,CO (% predicted) 65 ± 14.7
Values are expressed as mean ± SD.
Gold, Global Initiative for Chronic Obstructive Lung Disease.; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity.; DLCO, Diffusion capacity
lung for carbon monoxide.
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absolute and relative numbers of eosinophils and the
level of ECP in mannitol-induced sputum (r = 0.71, p =
0.001; r = 0.60, p = 0.008; r = 0.72, p = 0.001, respec-
tively) (Figure 3). In addition, RDR mannitol was related
to the levels IL-8 (r = 0.57, p = 0.015) and MPO (r =
0.64, p = 0.007) (Table 3).
Inflammatory markers as obtained by hypertonic- and
mannitol challenge were generally well correlated
(Table 4). The limits of agreement by Bland and Altman
analyses for eosinophil counts and log ECP were -5.7-8.6%
and -0.73-0.72, respectively.
ROC curves
The overall accuracy of RDR to mannitol for the assess-
ment of eosinophilic or non eosinophilic COPD,
described as the area under the ROC curve (Figure 4),
was 67% (95% CI, 33.6 to 97.5%) for hypertonic saline-
and 80% (95% CI, 47.7 to 112.3%) for mannitol-induced
sputum. At RDR of 0.08%fall.mg the sensitivity and spe-
cificity for >2.5% eosinophils in hypertonic saline-
induced sputum was 50% (95% CI, 11.8 to 88.2%) and
93% (95% CI, 68 to 99.8%), respectively. For mannitol-
induced sputum the sensitivity and specificity was 60%
Table 2 Patient characteristics II- Airway
hyperresponsiveness (AHR) and airway inflammation
Subjects n =2 8
Airway responsiveness (n= 26)
- AHR to mannitol*(n)1 8
- RDR mannitol (%/mg) 0.044 (0.0204-0.0605)
- Max dose of mannitol (mg) 395 (315-635)
-P D 15 mannitol** 331 (196-635)
Fraction Exhaled Nitric Oxide
- FeNO (ppb) 14 (9-22.5)
Sputum (n= 23)
- Eosinophils (%) 0.8 (0.4-3.1)
- Lymphocytes (%) 1.4 (1.0-2.4)
- Macrophages (%) 18.8 (12.8-22.2)
- Neutrophils (%) 77.2 (70.8-86.0)
- Total cell count (x10
6/g) 1.6 (0.5-2.8)
Blood (n= 28)
- Eosinophils (%) 2.7 (1.8-4.3)
- Neutrophils (%) 55.9 (49.8-61.8)
Values are expressed as median and interquartile range.
RDR, Response Dose Ratio (fall FEV1 divided by cumulative dose given); PD15,
Provocation Dose of mannitol to cause a 15% fall in FEV1; pbb, parts per
billion.
*: positive reaction to mannitol: PD15 <635 mg; **: including 8 patients who
did not reach a PD15, we used an assigned value of 635 mg.
Figure 2 Correlation AHR to mannitol and eosinophils in hypertonic saline-induced sputum (left), blood eosinophils (middle) and
fraction exhaled nitric oxide (right).
Table 3 Correlation between AHR to mannitol expressed
by the response-dose ratio (RDR) and markers of airway
inflammation
r p- value
FEV1 (% predicted) -0.09 0.67
Log FeNO 0.67 0.0002*
Hypertonic saline-induced sputum
Log (10
4/g) eosinophils 0.47 0.03*
Log (10
4/g) lymphocytes 0.18 0.45
Log (10
4/g) macrophages 0.27 0.24
Log (10
4/g) neutrophils 0.25 0.28
Log (10
4/g) epithelial cells 0.38 0.10
Log (ng/ml) ECP 0.39 0.09
Log (pg/ml) IL-8 0.46 0.04*
Log (ng/ml) MPO 0.33 0.14
Mannitol- induced sputum
Log (10
4/g) eosinophils 0.71 0.001*
Log (ng/ml) ECP 0.72 0.001*
Log (pg/ml) IL-8 0.57 0.015*
Log (ng/ml) MPO 0.64 0.007*
Venous blood
Log (%) eosinophils 0.38 0.06
Log (%) neutrophils -0.23 0.26
RDR is taken as the maximal% fall in FEV1 per cumulative dose; correlation:
Pearsons correlation coefficient; FeNO: fraction exhaled nitric oxide in parts
per billion. * p < 0.05.
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100%) respectively (Figure 4). When using a cut-point of
2.0% eosinophils we observed sensitivities of 44% (95%
CI, 13.7 to 78.8%) and 43% (95% CI, 9.0 to 81.6%) with
specificities of 100% (95% CI, 73.5 to 100.0%) and 100%
(95% CI, 71.5 to 100%) for hypertonic saline- and
mannitol- induced sputum, respectively.
Discussion
In this group of mild to moderate COPD patients, AHR
to inhaled mannitol was consistently associated with
eosinophil counts in hypertonic saline- as well as man-
nitol-induced sputum. In addition, we observed associa-
tions between AHR to mannitol and soluble markers of
inflammation in sputum. Our results suggest that man-
nitol challenge identifies inflammatory subphenotypes in
COPD, in particular those patients without eosinophilic
inflammation due to the high specificity of the test. This
may facilitate individualized treatment in COPD.
To our knowledge, this is the first study assessing the
relationship between airway hyperresponsiveness to
inhaled mannitol and markers of airway inflammation in
sputum and exhaled air in patients with COPD. These
observations extend previous findings in COPD using
adenosine 5’-monophosphate (AMP), in which a correla-
tion between AHR to AMP and eosinophils in sputum
was observed [24]. Interestingly, a similar correlation
between RDR to mannitol and sputum eosinophils was
recently reported in patients with asthma, also showing
absence of eosinophilia in patients without mannitol
hyperresponsiveness [13]. Hence, mannitol challenge
appears to provide valuable information on the inflamma-
tory profile in both patients with COPD and asthma.
In our study, particular attention was paid to metho-
dological aspects such as selection of COPD patients,
design and methods. The patients were derived from a
clinical population rather than an epidemiological one,
in order to strengthen the applicability of our findings.
All patients were well characterised by using subjective
and objective criteria. This included the presence of
symptoms, fixed airway obstruction and smoking his-
tory. The full range in sputum eosinophils counts was
0.1 to 7.4%, which is similar to previous studies in
COPD [3-5]. To exclude any confounding effects of
inhaled corticosteroids on mannitol challenge, the
patients who used inhaled corticosteroids stopped this
medication for 4 weeks [9,11]. In order to answer the
research question accurately, we performed mannitol
challenge and sputum induction on separate days. In
addition, we examined sputum expectorated after the
mannitol itself, which confirmed our results. Further-
more, as inflammatory markers we used both, the
presence of inflammatory cells and markers of cell acti-
vation. This provided consistent associations.
Nevertheless, our study has limitations. First, we could
not obtain adequate sputum samples in all patients at
all time points. Even though the power of the study was
adequate to address the primary objectives, it may not
have been adequate to examine our secondary objective.
Second, we can not exclude that our COPD group
included patients who also had asthma. We excluded
those with a previous history of asthma, but this may
not have sufficed. However, all patients had a smoking
Figure 3 Correlation AHR to mannitol and the absolute (left) and relative (middle) amount of eosinophils and ECP (right) in mannitol-
induced sputum.
Figure 4 ROC curve. The curve of sensitivity against 100-specificity
is based on using reactivity to mannitol, given as RDR values (%fall.
mg), to predict eosinophilic COPD (>2.5%) in hypertonic saline (left)
and mannitol-induced (right) sputum. Dotted line: line of identity.
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criteria, and were diagnosed and treated as COPD
patients. Third, the patients needed to stop the inhaled
corticosteroids in order to examine unbiased disease
markers. Therefore, the test performance cannot be gen-
eralized to COPD patients on inhaled steroids. This will
require a separate study. Finally, we did not include a
second mannitol challenge for examining reproducibility
of our results, which is a limitation of our design.
How can we interpret these results? Mannitol is an
osmotic stimulus that causes airway narrowing by
release of bronchoconstrictor mediators such as leuko-
trienes, prostaglandins and histamine [25,26]. The
source of these mediators is likely to be mast cells and
eosinophils in the airways as both these cell types
release mediators in vitro in response to mannitol
[10,11,27]. Mast cells and eosinophils are not unimpor-
tant in COPD and may contribute to the fluctuations of
airways obstruction as observed e.g. during exacerba-
tions [28-31]. We did not observe associations of manni-
tol responsiveness with neutrophil counts in sputum or
blood, but did found significant correlations with spu-
tum IL-8 and MPO. This may suggest that epithelial cell
and neutrophil activity are also involved in determining
the airway narrowing to inhaled mannitol in COPD.
Interestingly, mannitol responsiveness was more
strongly associated with FeNO than with sputum eosi-
nophils. However, we did not find a significant associa-
tion between the latter two parameters. This is in
keeping with the data by Siva et al. [6]. Our results sug-
gest that mannitol responsiveness is a better marker of
eosinophilic inflammation than FeNO in COPD.
Notably, we observed that most COPD patients pro-
duced adequate sputum samples during the mannitol
challenge. This occurred even in absence of encouraging
the patients to expectorate. Therefore, the success rate
of obtaining mannitol-induced sputum may well be
improved by adjusting the standard operating procedure
of the test. Our findings extend a recent study in
asthma, showing adequate sputum samples after manni-
tol challenge [32]. Inhaled mannitol changes osmolarity
and reduces viscoelasticity, surface tension, contact
angle and the solids content of sputum [33]. This may
explain why 75% of the patients gave up sputum during
mannitol challenge. Our results suggest that mannitol
activated eosinophils, neutrophils and epithelial cells.
Hence, even though AHR to mannitol was associated
with eosinophilic airway inflammation, it is likely to be
a more pleiotropic stimulus within the airways.
What are the clinical implications of our study? Eosi-
nophilic airway inflammation predicts the response of
COPD patients to systemic and inhaled corticosteroids
[4,5]. In addition, inhaled steroid therapy guided by spu-
tum eosinophils reduces exacerbation rate in patients
with COPD [6]. Our results suggest that mannitol chal-
lenge can identify COPD patients without eosinophilic
airway inflammation, who not likely to benefit from
inhaled steroid therapy [6]. This subphenotype of
patients cannot be distinguished from other patients
with COPD on clinical grounds or lung function criteria.
Therefore, mannitol challenge may qualify as a feasible
alternative in the monitoring of anti-inflammatory ther-
apy in COPD. The high specificity (100%) in combina-
tion with limited sensitivity indicates that mannitol
responsiveness is particularly suitable to exclude sputum
eosinophilia in COPD. Indeed, inhaled steroids appear
to be ineffective in COPD patients with the lowest
responsiveness to mannitol [14]. Therefore, mannitol
responsiveness may support decisions to refrain from
inhaled steroid treatment, thereby potentially preventing
overtreatment of COPD. This requires a randomized
controlled study in COPD comparing a treatment strat-
egy based on AHR to mannitol with the currently
recommended treatment strategy based on clinical
Table 4 Induced sputum total and differential cell count and mediators when collected with hypertonic saline or
mannitol (18 paired samples)
Hypertonic saline Mannitol induced r
Eosinophils (10
4/g) 1.1 (0.5-6.5) 0.9 (0.3-7.5) 0.81 (p = < 0.001*)
Lymphocytes (10
4/g) 1.8 (1.0-7.0) 1.9 (1.0-3.9) 0.37 (p= 0.132)
Macrophages (10
4/g) 31.7 (13.2-48.7) 20.5 (12.6-34.4)** 0.71 (p = 0.001*)
Neutrophils (10
4/g) 111.1 (59.4-231.5) 108.1 (58.4-160.1) 0.75 (p = < 0.001*)
Epithelial cells (10
4/g ) 21.3 (14.5-71.2) 25.5 (12.8-42.3) 0.61 (p = 0.009*)
Total cell count (×10
6/g) 1.6 (0.8-2.6) 1.4 (0.8-2.0) 0.73 (p = 0.001*)
Gram sputum 6.9 (5.2-10.9) 4.0 (2.0-9.0)** 0.60 (p = 0.006*)
ECP (ng/ml) 147.5 (89.5-492.3) 125.8 (64.1-277.2) 0.85 (p = < 0.001*)
IL-8 (pg/ml) 1925.5 (534.8-7076.0) 1595 (862.8-3357.2) 0.72 (p = 0.001*)
MPO (ng/ml) 4529.7(1779.4-7414.8) 5174.3(1203.0-11933) 0.84 (p = < 0.001*)
Data expressed as median and interquartile range; r= Pearsons correlation coefficient:
* = significant; **= significantly different (Wilcoxon rank test).
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nitol challenge can also be an outcome measure of the
efficacy of steroids in COPD, as has been shown in
asthma [12]. Finally, our data suggest that the assess-
ment of AHR and airway inflammation in COPD can be
combined in a single test. This would have large practi-
cal advantages, not only in clinical research, but also
regarding the guidance and monitoring of anti-inflam-
matory therapy in clinical practice.
Conclusions
We conclude that airway responsiveness to mannitol
can be used to rule out eosinophilic airway inflamma-
tion in patients with mild to moderate COPD who are
not treated with inhaled corticosteroids. These finding
suggests that mannitol challenge is a candidate for the
guidance and monitoring of individualized, anti-inflam-
matory therapy in COPD, as an alternative to sputum
eosinophils.
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AHR: airway hyperresponsiveness; ECP: eosinophil cationic protein; FeNO:
fraction exhaled nitric oxide; FEV1: forced expiratory volume in one second;
FEV1/FVC: forced vital capacity divided by the forced expiratory volume in
one second; FVC: forced vital capacity; ICS: inhaled corticosteroids; IL-8:
interleukin-8; MPO: myeloperoxidase; PD15: provocation dose to cause a fall
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